title: CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.
abstract: BACKGROUND
  Comparative genetic and biological studies on malignant tumor counterparts in human beings and laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocytes and plasma cells such as Burkitt lymphoma (BL) and multiple myeloma (MM).
  
  
  METHODS
  We used EMSA to detect constitutive NF-κB/STAT3 activity in BL- and MM-like neoplasms that spontaneously developed in single-transgenic IL6 (interleukin-6) or MYC (c-Myc) mice, or in double-transgenic IL6MYC mice. qPCR measurements and analysis of clinical BL and MM datasets were employed to validate candidate NF-κB/STAT3 target genes.
  
  
  RESULTS
  qPCR demonstrated that IL6- and/or MYC-dependent neoplasms in mice invariably contain elevated mRNA levels of the NF-κB target genes, Cdkn1a and Fancd2. Clinical studies on human CDKN1A, which encodes the cell cycle inhibitor and tumor suppressor p21, revealed that high p21 message predicts poor therapy response and survival in BL patients. Similarly, up-regulation of FANCD2, which encodes a key member of the Fanconi anemia and breast cancer pathway of DNA repair, was associated with poor outcome of patients with MM, particularly those with high-risk disease.
  
  
  CONCLUSIONS
  Our findings suggest that CDKN1A and FANCD2 are potential oncotargets in BL and MM, respectively. Additionally, the IL-6- and/or MYC-driven mouse models of human BL and MM used in this study may lend themselves to the biological validation of CDKN1A and FANCD2 as molecular targets for new approaches to cancer therapy and prevention.
authors.affiliation: Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Seong-Su
authors.initials: SS
authors.lastname: Han
authors.affiliation: Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Van S
authors.initials: VS
authors.lastname: Tompkins
authors.affiliation: School of Applied Biosciences, Kyungpook National University, Daegu, 702-701 South Korea.
authors.forename: Dong-Ju
authors.initials: DJ
authors.lastname: Son
authors.affiliation: Department of Health and Human Physiology, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Sangwoo
authors.initials: S
authors.lastname: Han
authors.affiliation: Department of Biological Sciences, Hanseo University, Choognam, South Korea.
authors.forename: Hwakyung
authors.initials: H
authors.lastname: Yun
authors.affiliation: Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Natalie L
authors.initials: NL
authors.lastname: Kamberos
authors.affiliation: Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Casey L
authors.initials: CL
authors.lastname: Dehoedt
authors.affiliation: Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Gu
authors.affiliation: Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Carol
authors.initials: C
authors.lastname: Holman
authors.affiliation: Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Guido
authors.initials: G
authors.lastname: Tricot
authors.affiliation: Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Fenghuang
authors.initials: F
authors.lastname: Zhan
authors.affiliation: Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA USA.
authors.forename: Siegfried
authors.initials: S
authors.lastname: Janz
keywords: Fanconi anemia and breast cancer DNA damage repair; Genetically engineered mouse models of human cancer; Molecularly targeted cancer therapy; p21 tumor suppressor
references.citation: Oncogene. 2001 Nov 22;20(53):7722-33
references.pmid: 11753650
references.citation: Cancer Lett. 2002 May 8;179(1):1-14
references.pmid: 11880176
references.citation: Science. 2005 Jan 14;307(5707):269-73
references.pmid: 15653507
references.citation: Int J Cancer. 1997 Aug 22;74(4):383-9
references.pmid: 9291426
references.citation: DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24
references.pmid: 16815105
references.citation: Cancer Res. 1995 Apr 1;55(7):1431-5
references.pmid: 7882347
references.citation: Biochemistry (Mosc). 2012 Jun;77(6):575-84
references.pmid: 22817456
references.citation: J Pathol. 1998 Mar;184(3):265-71
references.pmid: 9614378
references.citation: Ann Hematol. 2010 Apr;89(4):399-404
references.pmid: 19756599
references.citation: J Biomed Sci. 2012 Feb 04;19:15
references.pmid: 22305266
references.citation: Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1509-14
references.pmid: 11805288
references.citation: Lancet Oncol. 2011 Jul;12(7):617-9
references.pmid: 21664869
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14590-5
references.pmid: 9405657
references.citation: Cell. 1993 Nov 19;75(4):817-25
references.pmid: 8242752
references.citation: Biochem Biophys Res Commun. 2013 Jul 12;436(4):660-5
references.pmid: 23764397
references.citation: Blood. 2007 Mar 15;109(6):2276-84
references.pmid: 17105813
references.citation: Oncogene. 2012 Jan 19;31(3):366-75
references.pmid: 21685936
references.citation: Nature. 2009 Jan 1;457(7225):51-6
references.pmid: 19122635
references.citation: Biochim Biophys Acta. 2000 Jul 31;1471(1):M43-56
references.pmid: 10967424
references.citation: Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547-51
references.pmid: 2798426
references.citation: Am J Hematol. 2012 Jan;87(1):78-88
references.pmid: 22180161
references.citation: Blood. 2006 Sep 15;108(6):2020-8
references.pmid: 16728703
references.citation: Oral Oncol. 1998 May;34(3):198-203
references.pmid: 9692054
references.citation: Mol Cancer. 2010 Apr 30;9:97
references.pmid: 20433747
references.citation: Cancer Res. 2005 Feb 15;65(4):1306-15
references.pmid: 15735016
references.citation: Blood Cancer J. 2013 Nov 29;3:e165
references.pmid: 24292417
references.citation: PLoS Pathog. 2007 Nov;3(11):e166
references.pmid: 17997602
references.citation: Curr Opin Oncol. 2013 Jan;25(1):52-8
references.pmid: 23159848
references.citation: Mol Cell Biol. 2005 Aug;25(15):6592-602
references.pmid: 16024795
references.citation: Cancer Res. 2009 Dec 15;69(24):9367-75
references.pmid: 19934314
references.citation: Cancer Res. 2001 Aug 15;61(16):6234-8
references.pmid: 11507077
references.citation: Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):232-5
references.pmid: 1729694
references.citation: Int J Biochem Cell Biol. 2008;40(10 ):2065-77
references.pmid: 18378183
references.citation: J Am Soc Nephrol. 2004 Mar;15(3):585-91
references.pmid: 14978160
references.citation: N Engl J Med. 2006 Jun 8;354(23):2431-42
references.pmid: 16760443
references.citation: Blood. 2010 Mar 4;115(9):1746-54
references.pmid: 20018915
references.citation: Nat Rev Cancer. 2009 Jun;9(6):400-14
references.pmid: 19440234
references.citation: Mol Cancer Res. 2003 Feb;1(4):262-70
references.pmid: 12612054
references.citation: Cell. 1993 Nov 19;75(4):805-16
references.pmid: 8242751
references.citation: Int J Radiat Biol. 1998 Oct;74(4):481-9
references.pmid: 9798959
references.citation: Oncogene. 2006 Jul 6;25(29):4128-32
references.pmid: 16462758
references.citation: J Biol Chem. 2002 Nov 29;277(48):46093-100
references.pmid: 12324457
references.citation: Leuk Res. 2013 Feb;37(2):146-54
references.pmid: 23237561